SPOTLIGHT: Pharmstandard, Solvay ink deal


Contract manufacturer Pharmstandard inked a license-and-manufacturing deal with France's Solvay Pharma. In the deal's first phase, Pharmstandard will use imported Solvay compounds to formulate and package two drugs, Imudon and IRS 19, in Russia. Next, Pharmstandard will take on manufacturing of the compounds itself.  Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.